Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alpha Tau Medical Ltd ( (DRTS) ) has shared an update.
Alpha Tau Medical Ltd., the developer of the Alpha DaRT alpha-radiation cancer therapy, reported its full-year 2025 results on March 9, 2026, alongside a broad clinical and regulatory update. The company is expanding into major cancer indications such as pancreatic, prostate, and brain tumors, while scaling manufacturing at its New Hampshire facility to support anticipated commercial demand.
In recent months, Alpha Tau secured Japanese marketing approval for Alpha DaRT in unresectable locally advanced or recurrent head and neck cancer, its first approval outside Israel, and obtained FDA approval to launch a U.S. pilot trial in locally recurrent prostate cancer. It also treated the first patient in a U.S. recurrent glioblastoma trial, submitted the first module of a U.S. PMA for recurrent cutaneous squamous cell carcinoma, and reported encouraging pancreatic cancer data at the ASCO GI Symposium.
Looking ahead, the company targets completion of patient recruitment in its pivotal U.S. ReSTART skin cancer trial by the end of Q1 2026, its U.S. pancreatic cancer pilot study in Q2 2026, and its recurrent glioblastoma feasibility trial in the second half of 2026. These milestones, coupled with post-marketing surveillance obligations in Japan, are set to shape Alpha Tau’s regulatory and commercial trajectory across multiple high-need oncology markets.
Financially, Alpha Tau’s R&D expenses rose to $32.1 million in 2025 from $27.0 million in 2024, and G&A costs also increased, driving a wider net loss of $42.6 million, or $0.53 per share, versus a $31.8 million loss a year earlier. Despite the higher burn, the company ended 2025 with $76.9 million in cash, cash equivalents, and deposits, up from $62.9 million, supporting ongoing clinical development and pre-commercial activities.
The most recent analyst rating on (DRTS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
Overall score is held down primarily by very weak fundamentals (no revenue, ongoing losses, and persistent cash burn), with only partial support from an improved balance sheet. Technicals are a near-term positive with strong trend strength, but overbought momentum indicators add downside risk. Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli medical technology company developing Alpha DaRT, an alpha-radiation–based therapy designed for the treatment of solid tumors. The company is focused on difficult-to-treat cancers, including recurrent skin, head and neck, pancreatic, prostate, and brain cancers, and is building commercial-scale manufacturing capabilities in the U.S. while pursuing regulatory approvals globally.
Average Trading Volume: 360,873
Technical Sentiment Signal: Buy
Current Market Cap: $546.5M
For a thorough assessment of DRTS stock, go to TipRanks’ Stock Analysis page.